Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL)

17 - 19 May 2019

Vienna House Andels' Berlin Hotel, Berlin, Germany

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany

Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )

CNS involvement and prophylaxis in acute lymphoblastic leukaemia

Dr Mark Litzow - Mayo Clinic, Rochester, USA

CNS involvement and prophylaxis in acute lymphoblastic leukaemia ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

Indications for allogeneic haematopoietic stem cell transplantation in adult acute lymphoblastic leukaemia

Dr Mark Litzow - Mayo Clinic, Rochester, USA

Indications for allogeneic haematopoietic stem cell transplantation in adult acute lymphoblastic leukaemia ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

Metabolic vulnerability in NOTCH-driven T cell acute lymphoblastic leukaemia

Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK

Metabolic vulnerability in NOTCH-driven T cell acute lymphoblastic leukaemia ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )

MLL-rearranged acute lymphoblastic leukaemia

Dr Pablo Menéndez - Josep Carreras Leukemia Research Institute, Barcelona, Spain

MLL-rearranged acute lymphoblastic leukaemia ( Dr Pablo Menéndez - Josep Carreras Leukemia Research Institute, Barcelona, Spain )

Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia

Prof Max Topp - University of Würzburg, Würzburg, Germany

Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

MRD management in adults with acute lymphoblastic leukaemia

Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy

MRD management in adults with acute lymphoblastic leukaemia ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )

Using CAR T cells for the treatment of acute lymphoblastic leukaemia

Prof Claudia Rossig - Universität Münster, Münster, Germany

Using CAR T cells for the treatment of acute lymphoblastic leukaemia ( Prof Claudia Rossig - Universität Münster, Münster, Germany )

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia

Prof Hervé Dombret, University Paris Diderot, Paris, France

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Prof Hervé Dombret, University Paris Diderot, Paris, France )

Highlights from ICALL 2019

Prof Hervé Dombret - University Paris Diderot, Paris, France

Highlights from ICALL 2019 ( Prof Hervé Dombret - University Paris Diderot, Paris, France )

Precision diagnosis for tailored therapy in acute lymphoblastic leukaemia

Dr Jean-Pierre Bourquin - University Children’s Hospital, Zurich, Switzerland

Precision diagnosis for tailored therapy in acute lymphoblastic leukaemia ( Dr Jean-Pierre Bourquin - University Children’s Hospital, Zurich, Switzerland )

Integrating, balancing and disregarding risk factors in paediatric acute lymphoblastic leukaemia

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Integrating, balancing and disregarding risk factors in paediatric acute lymphoblastic leukaemia ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Epigenetic expression in T cell leukaemia

Dr Sinisa Dovat - Penn State Cancer Institute, Hershey, USA

Epigenetic expression in T cell leukaemia ( Dr Sinisa Dovat - Penn State Cancer Institute, Hershey, USA )

Managing metabolism and drug toxicity in acute lymphoblastic leukaemia

Dr Mary Relling - St Jude's Children's Research Hospital, Memphis, USA

Managing metabolism and drug toxicity in acute lymphoblastic leukaemia ( Dr Mary Relling - St Jude's Children's Research Hospital, Memphis, USA )

B-lymphoid transcriptional programme as a barrier against malignant transformation in acute lymphoblastic leukaemia

Prof Markus Müschen - City of Hope Comprehensive Cancer Center, Los Angeles, USA

B-lymphoid transcriptional programme as a barrier against malignant transformation in acute lymphoblastic leukaemia ( Prof Markus Müschen - City of Hope Comprehensive Cancer Center, Los Angeles, USA )

Individual management of acute lymphoblastic leukaemia in adolescents and young adults

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Individual management of acute lymphoblastic leukaemia in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Master pathways and targets in T cell acute lymphoblastic leukaemia

Prof Jean Soulier - Hôpital Saint Louis, Paris, France

Master pathways and targets in T cell acute lymphoblastic leukaemia ( Prof Jean Soulier - Hôpital Saint Louis, Paris, France )

T cell development and T cell leukaemia

Prof Hans-Reimer Rodewald - Universitätsklinikum Heidelberg, Heidelberg, Germany

T cell development and T cell leukaemia ( Prof Hans-Reimer Rodewald - Universitätsklinikum Heidelberg, Heidelberg, Germany )

More from ecancer